A Prospective, Two-center, Single Arm Phase II Clinical Study to Evaluate Safety and Effectiveness of Ablation Therapy in the Treatment of Lung Cancer Presenting as Ground-glass Nodules

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04905056

Enrollment

120

Registered

2021-05-27

Start date

2021-01-01

Completion date

2028-12-31

Last updated

2021-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Progression

Brief summary

A prospective, two-center, single arm phase II clinical study to evaluate safety and effectiveness of ablation therapy in the treatment of lung cancer presenting as ground-glass nodules

Interventions

OTHERAblation therapy

Ablation therapy in the treatment of lung cancer presenting as ground-glass nodules

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

1. Aged between 18 and 85 years; 2. GGO is diagnosed by lung CT and failure to subside after 3 months (the patient having been re-examined by thin-section CT); 3. The maximum diameter of the GGO is bigger than 8mm and smaller than 3cm; 4. For single GGO: obvious progress was observed in pure GGO or the solid component of mixed ground glass nodules was more than or equal to 2 mm 5. The patients were unable to tolerate the operation for various reasons or multiple grinding glass nodules, operation can not be completely removed; or patients had received surgery in ipsilateral chest 6. The patient is able to understand and comply with the study and has provided written informed consent

Exclusion criteria

1. Patients who participated in any drug and / or medical device clinical trials within one month before the trial 2. had severe disease conditions 3. allergy to narcotic drugs 4. had other autoimmune disease 5. dementia or cognitive impairment can't cooperate with researchers 6. any local treatment other than ablation was received within 4 weeks before the study

Design outcomes

Primary

Measure	Time frame	Description
progression free survival	1 years	One year progression free survival after radiofrequency ablation of ground glass nodules

Secondary

Measure	Time frame	Description
overall survival	1 years, 3 years, 5years	overall survival after radiofrequency ablation of ground glass nodules

Countries

China

Contacts

Primary ContactQun Wang, Phd

13301050210@fudan.edu.cn86-21-64041990

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026